Bank of America started coverage on shares of resTORbio (NASDAQ:TORC) in a research report released on Tuesday, February 20th, Marketbeat.com reports. The firm issued a buy rating and a $23.00 price target on the stock.
Separately, Evercore ISI initiated coverage on shares of resTORbio in a report on Tuesday, February 20th. They set an outperform rating and a $28.00 price objective on the stock.
resTORbio (TORC) traded down $0.37 during midday trading on Tuesday, reaching $15.08. 247,804 shares of the company traded hands, compared to its average volume of 115,397. resTORbio has a twelve month low of $14.56 and a twelve month high of $21.10.
WARNING: This piece of content was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/03/14/restorbio-torc-now-covered-by-bank-of-america.html.
resTORbio Company Profile
resTORbio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1).
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.